Contineum Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTNM research report →
Range $17 – $28
Price Chart
About the company
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
- CEO
- Carmine N. Stengone
- IPO
- 2024
- Employees
- 51
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CTNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $475.91M
- P/E
- -7.31
- PEG
- -0.31
- P/S
- 0.00
- P/B
- 1.98
- EV/EBITDA
- -7.09
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -24.73%
- ROIC
- -26.96%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-68,059,000
- Net Income
- $-59,978,000-41.9%
- EPS
- $-2.17-33.1%
- OCF Growth
- -68.4%
- FCF Growth
- -66.5%
- 52W High
- $17.79
- 52W Low
- $8.60
- 50D MA
- $14.86
- 200D MA
- $13.71
- Beta
- 0.75
- RSI (14)
- 41
- Avg Volume
- 496.94K
No earnings-call transcripts are available for CTNM yet.
- Free Float
- 73.8%
- Shares Outstanding
- 37.62M
- Float Shares
- 27.76M
of shares held by institutions
91 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Suvretta Capital Management, LLC | 2.84M | 0 |
| Jupiter Topco LLC | 2.73M | ▲ 2.73M |
| Janus Henderson Group Ltd. | 2.73M | ▲ 285.86K |
| Blackrock, Inc. | 2.06M | ▲ 1.40M |
| Johnson & Johnson | 1.98M | 0 |
| Franklin Resources Inc | 1.84M | 0 |
| Balyasny Asset Management L.P. | 1.52M | ▼ 162.84K |
| Vanguard Capital Management LLC | 1.32M | ▲ 107.18K |
| Vanguard Group Inc | 1.27M | ▲ 306.63K |
| Perceptive Advisors LLC | 1.26M | 0 |
| Fmr LLC | 1.04M | ▲ 225.26K |
| Millennium Management LLC | 931.71K | ▼ 603.74K |
Held by 124 ETFs
Biggest fund positions in CTNM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Stengone Carmine N. | other | 2,500 |
| Sep 8, 26 | Stengone Carmine N. | other | 2,500 |
| Sep 8, 26 | Stengone Carmine N. | sell | 2,500 |
| Aug 3, 26 | Stengone Carmine N. | other | 2,500 |
| Aug 3, 26 | Stengone Carmine N. | other | 2,500 |
| Aug 3, 26 | Stengone Carmine N. | sell | 2,500 |
| Jul 8, 26 | Lorrain Daniel S. | other | 1,015 |
| Jul 9, 26 | Lorrain Daniel S. | other | 25 |
| Jul 9, 26 | Lorrain Daniel S. | sell | 25 |
| Jul 8, 26 | Lorrain Daniel S. | other | 1,015 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTNM coverage
Recent articles, reports, and earnings notes.
No research on CTNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTNM report →48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC
defenseworld.net · Sep 25
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst Downgrade
defenseworld.net · Sep 16
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
benzinga.com · Sep 15
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
businesswire.com · Sep 14
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
businesswire.com · Aug 25
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
businesswire.com · Jul 30
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
zacks.com · Jul 9
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
gurufocus.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.